Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bramlage

Showing results (21-30 of 96) with videos related to

Pageof 10
Sort By:
MMW Fortschritte Der Medizin|October 20, 2004
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting]H Lehnert, P Bramlage, D Pittrow, et al.
Clinical Drug Investigation|May 23, 2007
Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment : an observational study in 38 016 patients in primary careH Lehnert, P Bramlage, D Pittrow, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|April 12, 2018
Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitusH Sims, K H Smith, P Bramlage, et al.
Deutsche Medizinische Wochenschrift (1946)|March 25, 2005
[Innovation instead of imitation -- news in drug therapy]E A Mueller, P Bramlage, W Böcking, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2015
Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectivesJoan Minguet, Katherine H Smith, Carsten P Bramlage, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|March 30, 2006
Cardiovascular risk management by blocking the endocannabinoid systemP Bramlage, I Mühlen, H Randeva, et al.
Der Unfallchirurg|September 13, 2011
[Prophylaxis of thromboembolic events in surgery. DVT prophylaxis: a comparison of out-patient and hospitalized patients]K Fecher, W Ewald, A Fürst, et al.
Allergy|August 29, 2009
Persistence with asthma treatment is low in Germany especially for controller medication - a population based study of 483,051 patientsJ Hasford, J Uricher, M Tauscher, et al.
MMW Fortschritte Der Medizin|March 8, 2008
[Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ]P Bramlage, E Schönrock, P Odoj, et al.
MMW Fortschritte Der Medizin|April 12, 2008
[Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ]P Bramlage, E Schönrock, P Odoj, et al.
Pageof 10

Showing results (21-30 of 96) with videos related to

Sort By:
Pageof 10
MMW Fortschritte Der Medizin|October 20, 2004
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting]H Lehnert, P Bramlage, D Pittrow, et al.
Clinical Drug Investigation|May 23, 2007
Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment : an observational study in 38 016 patients in primary careH Lehnert, P Bramlage, D Pittrow, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|April 12, 2018
Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitusH Sims, K H Smith, P Bramlage, et al.
Deutsche Medizinische Wochenschrift (1946)|March 25, 2005
[Innovation instead of imitation -- news in drug therapy]E A Mueller, P Bramlage, W Böcking, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2015
Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectivesJoan Minguet, Katherine H Smith, Carsten P Bramlage, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|March 30, 2006
Cardiovascular risk management by blocking the endocannabinoid systemP Bramlage, I Mühlen, H Randeva, et al.
Der Unfallchirurg|September 13, 2011
[Prophylaxis of thromboembolic events in surgery. DVT prophylaxis: a comparison of out-patient and hospitalized patients]K Fecher, W Ewald, A Fürst, et al.
Allergy|August 29, 2009
Persistence with asthma treatment is low in Germany especially for controller medication - a population based study of 483,051 patientsJ Hasford, J Uricher, M Tauscher, et al.
MMW Fortschritte Der Medizin|March 8, 2008
[Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ]P Bramlage, E Schönrock, P Odoj, et al.
MMW Fortschritte Der Medizin|April 12, 2008
[Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ]P Bramlage, E Schönrock, P Odoj, et al.
Pageof 10